LENZ Therapeutics Inc. (LENZ)
LENZ Therapeutics Statistics
Share Statistics
LENZ Therapeutics has 27.54M shares outstanding. The number of shares has increased by 7.87% in one year.
| Shares Outstanding | 27.54M |
| Shares Change (YoY) | 7.87% |
| Shares Change (QoQ) | 0.15% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 22.61M |
| Failed to Deliver (FTD) Shares | 80.63K |
| FTD / Avg. Volume | 39.23% |
Short Selling Information
The latest short interest is 2.45M, so 8.92% of the outstanding shares have been sold short.
| Short Interest | 2.45M |
| Short % of Shares Out | 8.92% |
| Short % of Float | 10.97% |
| Short Ratio (days to cover) | 16.01 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -14.63. LENZ Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -14.63 |
| PS Ratio | 0 |
| Forward PS | 1.5 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for LENZ Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.36, with a Debt / Equity ratio of 0.01.
| Current Ratio | 20.36 |
| Quick Ratio | 20.36 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-20.78M |
| Employee Count | 6 |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -124.65M |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -14.82% in the last 52 weeks. The beta is 0.42, so LENZ Therapeutics's price volatility has been higher than the market average.
| Beta | 0.42 |
| 52-Week Price Change | -14.82% |
| 50-Day Moving Average | 24.05 |
| 200-Day Moving Average | 25.46 |
| Relative Strength Index (RSI) | 32.21 |
| Average Volume (20 Days) | 205.53K |
Income Statement
| Revenue | n/a |
| Gross Profit | -2.41M |
| Operating Income | -73.11M |
| Net Income | -124.65M |
| EBITDA | -122.24M |
| EBIT | -124.65M |
| Earnings Per Share (EPS) | -15.3 |
Balance Sheet
The company has 20.16M in cash and 1.38M in debt, giving a net cash position of 18.78M.
| Cash & Cash Equivalents | 20.16M |
| Total Debt | 1.38M |
| Net Cash | 18.78M |
| Retained Earnings | -145.01M |
| Total Assets | 215.3M |
| Working Capital | 201.51M |
Cash Flow
In the last 12 months, operating cash flow was -59.39M and capital expenditures -468K, giving a free cash flow of -59.86M.
| Operating Cash Flow | -59.39M |
| Capital Expenditures | -468K |
| Free Cash Flow | -59.86M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LENZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LENZ is $37, which is 99.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $37 |
| Price Target Difference | 99.9% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Mar 22, 2024. It was a backward split with a ratio of 1:7.
| Last Split Date | Mar 22, 2024 |
| Split Type | backward |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | 26.27 |
| Piotroski F-Score | 0 |